Analysts Offer Insights on Healthcare Companies: Baxter International (BAX), Nautilus Biotechnolgy (NAUT) and Delcath Systems (DCTH)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Baxter International (BAX – Research Report), Nautilus Biotechnolgy (NAUT – Research Report) and Delcath Systems (DCTH – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Baxter International (BAX)
Citi analyst Joanne Wuensch maintained a Hold rating on Baxter International today. The company’s shares closed last Thursday at $20.36.
According to TipRanks.com, Wuensch is a 4-star analyst with an average return of
Baxter International has an analyst consensus of Hold, with a price target consensus of $19.90, implying a -4.5% downside from current levels. In a report issued on February 12, Stifel Nicolaus also maintained a Hold rating on the stock with a $20.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Nautilus Biotechnolgy (NAUT)
Guggenheim analyst Subbu Nambi reiterated a Buy rating on Nautilus Biotechnolgy yesterday and set a price target of $4.00. The company’s shares closed last Thursday at $2.42.
According to TipRanks.com, Nambi is a 5-star analyst with an average return of
Nautilus Biotechnolgy has an analyst consensus of Moderate Buy, with a price target consensus of $4.00, which is a 32.5% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock.
Delcath Systems (DCTH)
In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on Delcath Systems, with a price target of $21.00. The company’s shares closed last Thursday at $9.00.
According to TipRanks.com, Newman is a 2-star analyst with an average return of
Delcath Systems has an analyst consensus of Strong Buy, with a price target consensus of $23.80, representing a 152.4% upside. In a report released today, TipRanks – PerPlexity also upgraded the stock to Buy with a $10.00 price target.
